Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

被引：0
|
作者：
Baudin, E. [1 ]
Hoersch, D. [2 ]
Singh, S. [3 ]
Caplin, M. [4 ]
Ferone, D. [5 ]
Wolin, E. [6 ]
Capdevila, J. [7 ]
Buikhuisen, W. [8 ]
Raderer, M. [9 ]
Houchard, A. [10 ]
Thanh, Truong X. M. [10 ]
Reidy-Lagunes, D. [11 ]
机构：
[1] Gustave Roussy Inst Cancerol, Villejuif, France
[2] Zent Klin Bad Berka GmbH, Bad Berka, Germany
[3] Sunnybrook HSC, Sunnybrook Odette Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
[4] Royal Free Hosp, Sch Med, Neuroendocrine Tumour Unit, London, England
[5] Univ Genoa, Neuroendocrine Tumour Unit, Dept Internal Med & Med Specialties, Genoa, Italy
[6] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
[7] Vall dHebron Univ Hosp, Dept Med Oncol, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[8] Netherlands Canc Inst, Dept Thorax Oncol, Amsterdam, Netherlands
[9] Med Univ Vienna, Vienna, Austria
[10] Ipsen, Boulogne Billancourt, France
[11] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
bronchopulmonary neuroendocrine tumor; lanreotide autogel/depot; spinet; tumor growth rate; typical/atypical carcinoid;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I03
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [31] RESPONSE RATES IN THE PHASE 3 CLARINET TRIAL OF LANREOTIDE DEPOT VS PLACEBO IN PATIENTS WITH METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS).
    Iwasaki, Michiko
    Wolin, Edward
    Dasari, Arvind
    Liyanage, Nilani
    Lowenthal, Susan Pitman
    Phan, Alexandria
    ONCOLOGY NURSING FORUM, 2016, 43 (02) : 136 - 136
  • [32] Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study
    Pommier, Rodney F.
    Fisher, George A.
    Wolin, Edward M.
    Liyanage, Nilani
    Lowenthal, Susan Pitman
    Mirakhur, Beloo
    Shaheen, Montaser
    Vinik, Aaron I.
    PANCREAS, 2018, 47 (03) : 352 - 352
  • [33] Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study
    Fisher, G. A., Jr.
    Wolin, E.
    Kunz, P. L.
    Liyanage, N.
    Mirakhur, B.
    Lowenthal, S. Pitman
    Pommier, R. F.
    Shaheen, M.
    Vinik, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study
    Fisher, George A., Jr.
    Wolin, Edward M.
    Kunz, Pamela L.
    Liyanage, Nilani
    Mirakhur, Beloo
    Lowenthal, Susan Pitman
    Pommier, Rodney F.
    Shaheen, Montaser
    Vinik, Aaron
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S457 - S458
  • [35] An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)
    Duchateau, L.
    Lescrauwaet, B.
    Blot, K.
    Liyanage, N.
    Ray, D.
    Lowenthal, S. P.
    Braun, S.
    Mirakhur, B.
    NEUROENDOCRINOLOGY, 2017, 105 : 194 - 194
  • [36] Tumour Growth Rate (TGR) to Monitor Growth/Predict Response to Lanreotide Autogel (LAN) Use before, during and after Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs): Data from PRELUDE
    Prasad, V
    Srirajaskanthan, R.
    Grana, C. M.
    Baldari, S.
    Shah, T.
    Lamarca, A.
    Courbon, F.
    Scheidhauer, K.
    Baudin, E.
    Thanh, Truong X. M.
    Houchard, A.
    Bodei, L.
    NEUROENDOCRINOLOGY, 2019, 108 : 158 - 158
  • [37] Treatment Satisfaction, Symptom Control, and Quality of Life (QoL) With Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumor (NET) Patients With Carcinoid Syndrome (CS): Results From the SymNET Study
    Ruszniewski, Philippe
    Caplin, Martyn E.
    Valle, Juan W.
    Lombard-Bohas, Catherine
    Poston, Graeme
    Perros, Petros
    Holubec, Lubos
    Delle Fave, Gianfranco
    Smith, Denis
    Niccoli, Patricia
    Maisonobe, Pascal
    Gomez-Panzani, Edda
    PANCREAS, 2015, 44 (02) : 357 - 358
  • [38] A prospective, multicenter, single-arm, open-label, phase 3 study of Lanreotide Autogel (LAN) in Chinese patients with unresectable, locally advanced or metastatic grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Lu, M.
    Li, E.
    Cao, D.
    Chen, J.
    Zhang, N.
    Hu, H.
    Zou, J. Y.
    Shi, X.
    Truong, Thanh X. M.
    Shen, L.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 230 - 230
  • [39] The CLARINET Study - Assessing the Effect of Lanreotide Autogel on Tumor Progression-Free Survival in Patients with Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Joelle, Blumberg
    Nilani, Liyanage
    Martyn, Caplin
    PANCREAS, 2012, 41 (02) : 343 - 343
  • [40] Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study
    Lamarca, A.
    Crona, J.
    Ronot, M.
    Opalinska, M.
    Lopez Lopez, C.
    Pezzutti, D.
    Najran, P.
    Franca, R.
    Scaefer, N.
    Sundin, A.
    Pavel, M.
    Dromain, C.
    NEUROENDOCRINOLOGY, 2018, 106 : 178 - 178
12345